Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme
- 138 Downloads
Introduction: Carboxyamido-triazole (CAI) is a synthetic inhibitor of non-voltage-gated calcium channels that reversibly inhibits angiogenesis, tumor cell proliferation, and metastatic potential. This study examined the efficacy, safety and pharmacokinetics of oral CAI in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM) in an open-label, single arm non-randomized phase 2 trial.
Methods: Eligible patients with histologically confirmed GBM started CAI therapy (250 mg daily) on the first day of radiation (6000 cGy in 30 fractions) and continued until progression, unless side effects became intolerable. The primary outcome was survival compared to historical controls within the NABTT CNS Consortium database. Secondary outcomes included toxicity and pharmacokinetic parameters.
Results: Fifty-five patients were enrolled with a median Karnofsky performance status of 90 and age of 56 years. Forty-six (84%) of these patients had debulking surgeries and 52 have died. The median survival was 10.3 months (95% confidence interval (CI), 8.5–12.8) compared to 12.1 months (95% CI, 10.3–13.3) in the NABTT reference group (p = 0.97). Significant toxicities included 2 incidents of reversible vision loss. The mean CAI plasma concentration for patients taking enzyme inducing antiepileptic drugs (EIAED) was 1.35 ±1.22 compared to 4.06 ± 1.50 (p < 0.001) for subjects not taking these agents. Overall survival and grade ≥ 3 toxicities were comparable by EIAED status.
Conclusions: This study demonstrated that (1) CAI can be administered safely with concomitant cranial irradiation, (2) the pharmacokinetics of CAI are significantly affected by co-administration of EIAED, and (3) the survival of patients with newly diagnosed GBM was not improved with this novel agent, despite achieving adequate drug levels.
KeywordsCAI Phase II Angiogenesis GBM
enzyme inducing anticonvulsants
Karnofsky performance status
New Approaches to Brain Tumor Therapy
Supported by NIH grant #CA062475.
- 8.Kohn, EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E (1997) Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 15:1985–1993PubMedGoogle Scholar
- 9.Simmons BR, Bauer KS, McCall NA, Kohn E, William D (1997) An optimized method for the quantitation of carboxyamido-triazole (CAI) in human plasma with solid phase extraction and reverse phase HPLC. Anal Lett 30:2009–2021Google Scholar
- 11.Kalbfleisch JD, Prentice RL (1980) Estimation of the survivor function. In: The statistical analysis of failure time data. John Wiley and Sons, New York, pp 16–19Google Scholar
- 12.Cox DR (1972) Regression models and life tables (with discussion). JR Stat Soc B 34:187–220Google Scholar
- 14.Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Lesser G, Ruffer J, Gerber M (1999) For the new approaches to brain tumor therapy central nervous system consortium. Phase I trial to determine the safety, pharmacodynamics and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J Clin Oncol 17:2593–2603PubMedGoogle Scholar
- 15.Kleinberg L, Grossman SA, Carson K, Lesser G, O’Neill A, Pearlman J, Phillips P, Herman T, Gerber M (2002) Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy cns consortium safety and efficacy study. J Clin Oncol 20:3149–3155PubMedCrossRefGoogle Scholar
- 17.Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, Grochow LB, Piantadosi S (1998) Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol 42:118–126PubMedCrossRefGoogle Scholar